Because of its merits, it has been approved for first‐line treatment for NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutations and EGFR T790M mutation‐positive NSCLC in 2018 and 2015, respectively. Here, EGFR is linked to non-small cell lung carcinoma.